December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
APOLLO met its primary endpoint of significantly improved PFS with daratumumab SC + Pd vs Pd only in patients with relapsed/refractory MM previously treated with lenalidomide and a PI.